Search
Zofin
go.drugbank.com/drugs/DB16519InvestigationalZofin, previously known as Organicell Flow, is a nanoparticle-based therapeutic derived from perinatal sources which is manufactured in a way that retains the naturally occurring microRNAs without the
Barbexaclone
go.drugbank.com/drugs/DB09001ExperimentalSeveral reports from Spanish and Italian literature suggest that barbexaclone is at least as effective as phenobarbital in adults and children, while being better tolerated and having less sedative properties … By weight, barbexaclone is 40% propylhexedrine and 60% phenobarbital.
Lutropin alfa
go.drugbank.com/drugs/DB00044ApprovedInvestigationalLutropin alfa was the first and only recombinant human form of luteinizing hormone (LH) developed for use in the stimulation of follicular development.
Nadofaragene firadenovec
go.drugbank.com/drugs/DB17381ApprovedInvestigationalIt is the first gene therapy approved by the FDA for the treatment of bladder cancer.[L44381,L44431] BCG-unresponsive NMIBC has a high recurrence and is notably difficult to treat. … [L44381] It was approved by the FDA on December 2022 for the treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma _in situ_ (CIS)
Brincidofovir
go.drugbank.com/drugs/DB12151ApprovedInvestigationalBrincidofovir, developed by Chimerix under the brand name Tembexa, was approved by the FDA for the treatment of smallpox infection in June 2021.
VE303
go.drugbank.com/drugs/DB17794InvestigationalVE303 is under clinical development by Vedanta Biosciences.
Dichlorophen
go.drugbank.com/drugs/DB11396InvestigationalVet approvedIt is often combined with toluene to remove parasites including ascarids, tapeworm, and hookworm from dogs and cats.
Quinine
go.drugbank.com/drugs/DB00468ApprovedInvestigationalAn alkaloid derived from the bark of the cinchona tree.
Lomustine
go.drugbank.com/drugs/DB01206ApprovedInvestigationalAn alkylating agent of value against both hematologic malignancies and solid tumors.
Synonyms: N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosoureaAvutometinib
go.drugbank.com/drugs/DB15254ApprovedInvestigational[A273948] Avutometinib was approved by the US FDA in May 2025 in a co-package alongside [defactinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian cancer
Synonyms: N-(3-fluoro-4-((4-methyl-2-oxo-7-((pyrimidin-2-yl)oxy)-2H-1-benzopyran-3-yl)methyl)pyridin-2-yl)-N'-methylsulfuric diamide, Sulfamide, N-(3-fluoro-4-((4-methyl-2-oxo-7-(2-pyrimidinyloxy)-2H-1-benzopyran-3-yl)methyl)-2-pyridinyl)-N'-methyl-